Promising Medicines in Clinical Trials

Participation of pathogenic antibodies in the pathogenic process of MS is assumed at least in some of the patients. Therefore, liquidation of the cells, which have the potential of maturing into cells creating antibodies (plasmacytes), is a logical method of treatment.

Research into MS works with a humanised antibody called ocrelizumab. It is administered as infusion once every 6 months; the number of B lymphocytes in peripheral blood is monitored.

Daclizumab is another monoclonal antibody. In patients who have a good therapeutic response, it increases the number of natural killers (NK cells), of which there is a deficit in patients with MS. Daclizumab is administered through subcutaneous injection once a month. The number of infections may increase; serious skin reactions may occur. It is necessary to monitor total blood count and liver functions.

A number of other medicines that act similarly as fingolimod are in clinical trials.